Metal Chelation Therapy

Major Chelating Agents#

EDTA (Ethylenediaminetetraacetic acid)#

• Target metals: Lead, cadmium, zinc, calcium
• Route: IV infusion (CaNa2EDTA to avoid hypocalcemia)
• Clinical use: Acute lead poisoning; the TACT trial showed modest benefit in post-MI diabetic patients with elevated lead
• Limitations: Poor oral bioavailability; non-selective (depletes zinc (Zn), copper (Cu), manganese (Mn))

DMSA (Succimer / Dimercaptosuccinic acid)#

• Target metals: Lead, Mercury, Arsenic
• Route: Oral
• Clinical use: FDA-approved for lead poisoning in children (blood lead (Pb) >45 mcg/dL). First-line pediatric chelator due to oral administration and relative safety.
• Limitations: Does not cross blood-brain barrier effectively; may redistribute metals if given before source removal

DMPS (2,3-Dimercapto-1-propanesulfonic acid / Unithiol)#

• Target metals: Mercury (especially inorganic), Arsenic, Lead
• Route: Oral or IV
• Clinical use: Mercury poisoning (preferred over DMSA for inorganic mercury (Hg)); arsenic poisoning. Not FDA-approved in the US but used widely in Europe.
• Limitations: Can mobilize mercury from tissue stores; renal excretion requires adequate kidney function

D-Penicillamine#

• Target metals: Copper, Lead, mercury
• Route: Oral
• Clinical use: Wilson's disease (Copper overload)—historical first-line agent. Also used in lead and mercury poisoning when DMSA/DMPS unavailable.
• Limitations: Significant side effects (nephrotoxicity, bone marrow suppression, autoimmune reactions); largely supplanted by trientine for Wilson's disease

Deferoxamine (Desferal)#

• Target metals: Iron
• Route: SC or IV infusion (poorly absorbed orally)
• Clinical use: Acute iron poisoning; chronic iron overload from transfusion-dependent thalassemia. The siderophore-derived chelator with highest iron specificity.
• Limitations: Requires prolonged infusion (8-12 hrs SC); ototoxicity, retinal toxicity with chronic use

Deferasirox (Exjade/Jadenu)#

• Target metals: Iron
• Route: Oral (once daily)
• Clinical use: Chronic transfusional iron overload. Revolutionized iron chelation by replacing deferoxamine infusions with oral dosing.
• Limitations: Hepatotoxicity, nephrotoxicity; GI side effects; expensive

Disulfiram / Diethyldithiocarbamate (DDC)#

• Target metals: Nickel, copper
• Route: Oral
• Clinical use: Nickel carbonyl poisoning (the specific antidote). DDC, the active metabolite of disulfiram (Antabuse), chelates nickel (Ni)(II) with high affinity. Also explored for copper chelation in cancer therapy.
• Limitations: Disulfiram-alcohol reaction; hepatotoxicity; limited clinical experience outside nickel carbonyl poisoning

Risks and Controversies#

Essential Metal Depletion#

No chelator is perfectly selective. EDTA depletes zinc and calcium. DMSA can lower zinc and copper.

Deferoxamine given to iron-replete individuals causes iron deficiency. This creates a paradox: chelation of one toxic metal may induce deficiency of another essential metal, potentially worsening disease through Mis-Metallation.

Redistribution#

Chelators can mobilize metals from stable tissue depots into the bloodstream, potentially increasing exposure to vulnerable organs (especially the brain) before the complex is excreted. This is particularly concerning for mercury and lead.

The Autism Controversy#

Chelation therapy has been promoted in alternative medicine for Autism Spectrum Disorder based on the theory that mercury (from thimerosal in vaccines) causes autism. Multiple systematic reviews find no evidence supporting this practice. The FDA has warned against over-the-counter chelation products.

At least one child death has been attributed to inappropriate EDTA chelation.

Chelation vs. Microbiome#

An underexplored dimension: chelation alters luminal metal availability, which directly impacts the Gut-Metal-Microbiome Interactions. Removing iron via chelation could starve iron-dependent pathobionts but also deprive beneficial Lactobacillus species. The microbiome consequences of chelation therapy remain largely unstudied.